EXELIXIS, INC. EXEL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
6/9
Piotroski F — financial health
7.69
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2026 | $2.3B | $782.6M | — | $875.8M | $2.2B |
| 2025 | $2.2B | $521.3M | — | $671.5M | $2.2B |
| 2023 | $1.8B | $207.8M | — | $292.9M | $2.3B |
| 2022 | $1.6B | $182.3M | — | $334.9M | $2.5B |
| 2021 | $1.4B | $231.1M | — | $346.6M | $2.2B |
| 2021 | $987.5M | $111.8M | — | $178.6M | $1.9B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | director | 2026-06-01 | Sell | 3,925 | $50.55 |
| Eckhardt Sue Gail | director | 2026-06-01 | Sell | 9,812 | $50.14 |
| PAPADOPOULOS STELIOS | director | 2026-05-27 | Grant | 8,367 | — |
| Heyman Tomas J. | director | 2026-05-27 | Grant | 8,367 | — |
| Eckhardt Sue Gail | director | 2026-05-27 | Grant | 8,367 | — |
| Smith Julie | director | 2026-05-27 | Grant | 8,367 | — |
| Freire Maria C | director | 2026-05-27 | Grant | 8,367 | — |
| Beckerle Mary C | director | 2026-05-27 | Grant | 8,367 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.69 (safe)
- Working capital / assets 0.365
- Retained earnings / assets -0.027
- EBIT / assets 0.307
- Equity / liabilities 3.164
Source: SEC EDGAR filings · CIK 0000939767 · as of 2026-01-02. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.